Harbour BioMed Public Relations
E-mail: pr@harbourbiomed.com
Harbour BioMed will partner with Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize its Phase II cancer immunotherapy candidate A167 worldwide except greater China, through an exclusive collaboration that could generate more than $350 million for Kelun-Biotech, the companies said today.
Harbour BioMed Public Relations
E-mail: pr@harbourbiomed.com